歸創通橋-B(02190.HK)上半年營收同比增長59.04% 經調整溢利淨額達7820萬元
格隆匯8月20日丨歸創通橋-B(02190.HK)公佈中期業績，2024年上半年，公司繼續致力於提高醫療服務的可及性，為患者恒創新，在產品研發、生產及商業化方面穩步推進核心能力。於報吿期內，實現收入人民幣3.66億元，同比增長59.04%，其中人民幣3.64億元來自介入產品的銷售，較2023年上半年增加58.2%。公司介入產品收入的66.9%來自神經血管介入產品業務，33.1%來自外周血管介入產品業務。公司收入的顯著增長主要歸因於神經血管和外周血管介入器械分部的銷售額高速增長。
報吿期內，公司實現非《國際財務報吿準則》經調整溢利淨額人民幣7820萬元，即經剔除以股份支付為基礎的薪酬開支調整後的期內溢利，以及公司權益持有人應占溢利淨額人民幣6890萬元。
於報吿期內，神經血管介入產品的銷售收入較2023年上半年增加46.7%，主要是由於(i)銀蛇顱內支持導管、鳳顱內動脈瘤栓塞彈簧圈、蛟龍取栓支架(蛟龍CRD)及白駒顱內PTA球囊擴張導管(Rx)等主要產品的收入持續增長；(ii)我們持續致力於提高產品在各級醫院的滲透率；及(iii)新產品如通橋麒麟血流導向裝置帶來的額外收入。
於報吿期內，外周血管介入產品的銷售收入較2023年上半年增加88.2%，原因是我們的UltraFree藥物洗脱PTA球囊擴張導管(UltraFree DCB)、ZENFLOW外周PTA球囊擴張導管、ZENFLOW高壓PTA球囊擴張導管及ZYLOX Swan靜脈腔內射頻閉合導管的銷售收入快速增長。該增長乃由於(i)我們不斷努力擴大市場準入、提高醫院滲透率及擴大分銷網絡；及(ii)我們持續豐富外周疾病治療產品組合，特別是ZYLOX Penguin靜至髂靜脈支架系統及ZYLOX Phoenix外周可解脱帶纖維毛彈簧圈栓塞系統的商業化上市，於2024年上半年創造了額外收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
